GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Return-on-Tangible-Equity

MedMira (MedMira) Return-on-Tangible-Equity : 0.00% (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MedMira's annualized net income for the quarter that ended in Jan. 2024 was $-1.76 Mil. MedMira's average shareholder tangible equity for the quarter that ended in Jan. 2024 was $-11.76 Mil. Therefore, MedMira's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 was N/A%.

The historical rank and industry rank for MedMira's Return-on-Tangible-Equity or its related term are showing as below:

MMIRF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -47.52
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

MedMira Return-on-Tangible-Equity Historical Data

The historical data trend for MedMira's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Return-on-Tangible-Equity Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedMira's Return-on-Tangible-Equity

For the Biotechnology subindustry, MedMira's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where MedMira's Return-on-Tangible-Equity falls into.



MedMira Return-on-Tangible-Equity Calculation

MedMira's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jul. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=-2.026/( (-9.552+-11.378 )/ 2 )
=-2.026/-10.465
=N/A %

MedMira's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=-1.76/( (-11.532+-11.98)/ 2 )
=-1.76/-11.756
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


MedMira  (OTCPK:MMIRF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


MedMira Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of MedMira's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira Reports First Quarter Results FY2023

By ACCESSWIRE ACCESSWIRE 12-31-2022

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018